References
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625–38.
National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0. Accessed August 29, 2019. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
Liu D, Zhao J. Cytokine release syndrome: Grading, modeling, and new therapy. J Hematol Oncol. 2018;11:121.
Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, et al. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018;24:1664–70.
Abboud R, Keller J, Slade M, et al. Severe Cytokine-Release Syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22:1851–60.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raj, R., Uppuluri, R. & VS, V. Tocilizumab Use in Children with Cytokine Release Syndrome. Indian Pediatr 58, 186–187 (2021). https://doi.org/10.1007/s13312-021-2142-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-021-2142-5